SanguiBioTech: SastoMed Closes Contracts with Distribution Partners in Six Additional Markets in Eastern Europe
February 03 2015 - 9:00AM
Business Wire
SastoMed GmbH has informed Sangui of having closed contracts for
initiating distribution and sales of the Sangui developed dressing
material Granulox in six Eastern European countries. In 2015 the
three Baltic countries will join the family of Granulox territories
along with the Czech Republic, Slovakia and Hungary.
Like in three Scandinavian markets it will be an enterprise
belonging to the Mediq group which will start initiating the
distribution in Estonia, Latvia and Lithuania. Mediq Eesti OÜ
(www.mediq.ee) is a wholesale company which has been successfully
trading medical and health care products throughout the Baltic
countries for many years. Its core business is in medical products
and laboratory equipment. A care a.s. (http://www.acare.cz/cs) was
entrusted with the Granulox business in the Czech Republic and in
Slovakia. The company specializes in medical products, in
particular in the fields of wound management, interventional
cardiology and radiology as well as neuroradiology. Halley Pharma
Ltd. (http://halleypharma.com) will look after the Hungarian market
in which they already distribute a wide array of other wound
management products.
In total there are distribution partnerships in place now for 40
countries worldwide, in 24 of which Granulox is already available
for doctors and patients. In the remaining 16 countries market
entry is scheduled for the next few months after the training of
the sales force will have been completed, or after the local
registration procedures will have been accomplished, respectively,
which is the case in some Central and South American countries.
Sangui BioTech International, Inc. ("SGBI") is a holding company
the shares of which are being traded on the OTCQB marketplace
(www.otcmarkets.com: SGBI) and the OTC markets of Berlin and
Hamburg-Hannover stock exchanges. Its purpose is to provide
financing and access to the capital markets for the enterprises of
the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary
of Sangui BioTech International, Inc.
Some of the statements contained in this news release discuss
future expectations, contain projections of results of operation or
financial condition or state other “forward-looking” information.
These statements are subject to known and unknown risks,
uncertainties, and other factors that could cause the actual
results to differ materially from those contemplated by the
statements. The forward-looking information is based on various
factors and is derived using numerous assumptions. Important
factors that may cause actual results to differ from projections
include, among many others, the ability of the Company to raise
sufficient capital to meet operating requirements. Words such as
“anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,”
“estimates,” and variations of such words and similar expressions
are intended to identify such forward-looking statements. Unless
required by law, the Company undertakes no obligation to update
publicly any forward-looking statements, whether as a result of new
information, future events or otherwise
Sangui BioTechJoachim FleingPhone: +49 (179) 7963472Fax: +49
(2302) 915191e-mail: fleing@sangui.de
Sangui Biotech (CE) (USOTC:SGBI)
Historical Stock Chart
From Jan 2025 to Feb 2025
Sangui Biotech (CE) (USOTC:SGBI)
Historical Stock Chart
From Feb 2024 to Feb 2025